Cancer Research and Biotechnology AG

Menu

CRB has a clear vision to develop several unique oncology drugs, targeting aggressive cancers with high unmet medical need.

CRB is improving patient journey via an accelerated clinical regulatory pathway, aiming to reduce the burden of conventional treatments.

CRB aims to create cancer drugs accessible to every patient around the world.

Proven efficacy

CRB091 shows a strong efficacy in pre-clinical trials against TNBC cells and other deadly cancers

Proven safety

The small molecules of CRB091 are approved safe for human use, and do not induce toxicity in healthy cells

Fast path to
first in-human

Accelerated path to first in-human is based on decades of existing research

High impact
on patients

Visible path to first-in-human, today in preclinical studies of pancreatic cancer, triple-negative breast cancer, and colon cancer

Pipeline

CRB is dedicated to developing safe and efficient drugs for the treatment of aggressive cancers. The first drug, CRB091, is targeted against Triple Negative Breast Cancer (TNBC) as first indication.

Other indications, including colorectal cancer and pancreatic cancer, are undergoing pre-clinical studies. They will follow a fast regulatory pathway to first in-human.

Drug Development
Discovery Target Validation Lead Optimization IND Clinical Trial Phase 1
NTE ONCOLOGY: TNBC - CRB091
NTE ONCOLOGY: CRC - CRB092
NTE ONCOLOGY: PC - CRB093
NTE/NCE ONCOLOGY
  • NTE= New Therapeutic Entity
  • NCE=New Chemical Entity
  • TNB=Triple Negative Breast Cancer
  • CRC=Colorectal Cancer
  • PC=Pancreatic Cancer

Team

KARI SARVANTO

CEO and Founder

Kai Karttunen

Chair and Co-Founder

Sam McQuade

Chief Financial Officer

Sarah Haddad

PhD: Senior Scientist

Pekka Lukkari

PhD: Regulatory Manager, EU

STAGE-DEPENDENT CONTRIBUTION

Research and
development,
Pre-Clinical

Drug
Development
and CMC

Regulatory
Affairs,
US

Clinical Affairs

Medical Affairs